Therefore, whether PXN-AS1 could be chosen as a therapeutic target to combat BCR::ABL1-independent resistance to TKIs in CML remains to be a long way to go. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.